1. Introduction {#sec1}
===============

Neoplastic meningitis is a central nervous system complication that occurs in 3--5% of patients with cancer \[[@B1]\], and it is most commonly seen in patients with disseminated progressive systemic disease due to spread of malignant cells to the leptomeninges. The most common primary tumors to metastasize to the meninges are lung cancer (9--25% of patients) \[[@B2]\] and melanoma (23%) \[[@B3]\], due to a distinctive neurotropism. More rarely neoplastic meningitis is the initial manifestation of systemic cancer (5--10%) \[[@B1]\] or it is primitive in origin, as it occurs in primary leptomeningeal melanomatosis \[[@B4]\]. In patients without cancer history, diagnosis may be challenging even for expert neurologists due to the lack of specific signs and symptoms. Prognosis of neoplastic meningitis is poor, as most untreated patients die within 1--9 weeks from diagnosis (median 3 weeks) \[[@B1], [@B5]\], as a result of neurological disease or tumor progression. The timeliness of diagnosis is crucial to start the appropriate treatment before sudden neurological deterioration.

Here, we present a retrospective series of three patients with meningeal melanomatosis without history of cancer, characterized by a dramatic diagnostic delay. We also propose an algorithm focused on the diagnosis of neoplastic meningitis in naïve patients.

2. Materials and Methods {#sec2}
========================

We describe a retrospective series of three patients with meningeal melanomatosis recruited from our two institutions (C. Mondino National Neurological Institute and Policlinico San Matteo Foundation IRCCS, Pavia, Italy) in four years. We conducted an Internal Review Board approved study using an institutional oncological database of all patients receiving a diagnosis of meningeal melanomatosis from January 2010 to January 2014. The medical records were reviewed and clinical, biological, and radiological data collected for details.

3. Results {#sec3}
==========

The clinical and paraclinical characteristics of our three patients are summarized in [Table 1](#tab1){ref-type="table"}. Patients were aged between 17 and 65. All patients had no previous cancer history and arrived to our centers after several neurologic evaluations. Clinical presentation included diffuse and/or multifocal neurological signs and symptoms: headache, nausea and/or vomiting, monoparesis, and cranial nerve palsies. One patient (patient 3) presented recurrent isolated confusional episodes but was completely asymptomatic in between. Electroencephalogram showed bilateral/diffuse slow abnormalities without epileptic activity in all cases. Brain MRI performed within the first 4 weeks from symptom onset was normal in both patients in whom it was acquired (pt 1 and 3). Alternatively, focal or diffuse nodular enhancement of leptomeninges and cranial nerves was documented ([Figure 1](#fig1){ref-type="fig"}). Spine MRI revealed nodular contrast enhancement of meninges, conus, and cauda, suggesting neoplastic infiltration ([Figure 2](#fig2){ref-type="fig"}). Cerebrospinal fluid (CSF) analysis showed severe blood-CSF barrier (B-CSF B) damage in all patients but inconstant pleocytosis. In patient 2, despite repeated lumbar punctures, CSF cytology remained negative and diagnosis was confirmed on leptomeningeal tissue obtained from biopsy. In all other patients, the presence of melanoma cells in the CSF (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) was eventually documented by means of repeated lumbar punctures. After the diagnosis of meningeal melanomatosis was confirmed, all patients underwent a chest-abdomen CT scan and a dermatological and an ophthalmological assessment. In two patients, the final diagnosis was of probable primary leptomeningeal melanomatosis (pt 1 and 2), while in patient 3 a cutaneous melanoma of right eyelid was documented. The diagnostic delay was remarkable in our series, with a median delay of 32 weeks from symptom onset (range: 17--47 weeks). Prognosis was dismal, with a median survival of 4.14 weeks from diagnosis (range: 2--6.29 weeks).

4. Discussion {#sec4}
=============

Although restricted, our series offers several insights into the diagnosis of neoplastic meningitis in naïve patients. These patients, without a previous cancer history, can present with diffuse/multifocal clinical signs and symptoms and represent a real diagnostic challenge. On these grounds, we propose an algorithm ([Figure 5](#fig5){ref-type="fig"}) to guide the clinician in the complex process of differential diagnosis, regarding as opening scenario a naïf patient presenting with subacute headache and/or encephalopathy plus one or more focal signs, and negative or inconclusive MRI, as we have observed in our series. In this setting, CSF analysis should be promptly performed to exclude other dysimmune/infectious disorders such as autoimmune and paraneoplastic encephalitides, primary CNS vasculitis, and chronic infectious meningitis, which can course without MRI alterations. Besides, it is important to consider that a delay in the diagnosis of the above-mentioned conditions may strongly affect final outcome and long-term sequelae.

Furthermore, even when the diagnosis of neoplastic meningitis has been suspected, paraclinical findings could be inconclusive. According to the literature, brain MRI has an estimated sensitivity of 40--60% in demonstrating meningeal neoplastic infiltration \[[@B1], [@B6], [@B7]\], but data correlating sensitivity of MRI to the timing of its execution are currently unavailable. In our series, brain MRI performed within the first month from onset was normal despite the clinical pattern was dominated by cerebral involvement. In the absence of meningeal contrast enhancement, dilation of the ventricular system or reduction of subarachnoid sulci may be indirect signs of neoplastic meningitis and should be valued in all cases.

CSF analysis, which was performed with remarkable delay in our series, showed a significant protein increase due to severe B-CSF B damage in all patients. Noteworthy, despite the delay and repeated sampling, in patient 2 CSF results were inconclusive for the detection of neoplastic cells, leading to performing a meningeal biopsy. Interestingly, CSF cytology can be persistently negative even in the presence of disseminated cranial and spinal disease on MRI. These data are consistent with current evidence that malignant cells are detected in the CSF in 50--70% of patients with neoplastic meningitis by initial lumbar puncture \[[@B1], [@B8], [@B9]\], a rate that increases with repeated sampling. In the case of normal or inconclusive CSF findings, a spine MRI may be helpful to demonstrate meningeal infiltration of cauda roots, even in the absence of spinal symptoms.

Overall, diagnostic difficulties resulted in a dramatic diagnostic delay, ranging from 17 to 47 weeks after clinical onset. These data are remarkable considering the poor short-term prognosis of these patients \[[@B10]\], who could access only palliative or even no treatment.

In conclusion, the difficulty in both posing the clinical suspicion and confirming the diagnosis of neoplastic meningitis contributed to the sharp diagnostic delay observed in our series. Early recognition is fundamental to make differential diagnosis and start appropriate therapies. Thus, improving the handle of these patients and the current diagnostic algorithms for neoplastic meningitis is of capital importance to offer them appropriate treatments.
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![Brain diffuse leptomeningeal melanomatosis in patient 1. (a), (b): T1 weighted axial image (TR/TE 1157 ms/45 ms) shows diffuse sulcal signal hyperintensity due to melanin products which cause T1 shortening signal. (c), (d): contrast-enhanced T1-weighted volume image (TR/TE 25 ms/4,6 ms) shows prominent and extensive leptomeningeal enhancement.](BMRI2015-948497.001){#fig1}

![Primary leptomeningeal melanomatosis in patients 1 ((a), (b)) and 2 ((c), (d)). (a), (c): Sagittal T2-weighted images (TR/TE 3500 ms/120 ms) of cervical-dorsal spine and cauda equina show hypertrophic leptomeninges with crowded subarachnoid space and multinodular appearance of the cauda equina. (b), (d): Sagittal T1-weighted images (TR/TE 65 ms/9 ms) of cervical-dorsal spine and cauda equina show diffuse leptomeningeal enhancement and thickening.](BMRI2015-948497.002){#fig2}

![Light microscopy pictures of the cytological specimen of cerebrospinal fluid obtained from patient 1: (a) hematoxylin and eosin staining of the hypercellular sample, with large, hyperchromatic cells associated with erythrocytes; (b) atypical cells stained with Melan-A, a melanoma-specific marker; (c) Schmorl staining confirmed the presence of melanin (blue granular stain) in the cytoplasm; magnification, 20x.](BMRI2015-948497.003){#fig3}

![Light microscopy pictures of the cytospin of the cerebrospinal fluid cells from patient 1: (a) hematoxylin and eosin staining of large, hyperchromatic cells, along with erythrocytes, lymphoma monocytoid cells, and eosinophils (asterisks); (b) an atypical cell at larger magnification; arrows indicate granules of melanin.](BMRI2015-948497.004){#fig4}

![The proposed algorithm for the diagnosis of neoplastic meningitis in naïve patients. B-CSF B = blood-cerebrospinal fluid barrier, CSF = cerebrospinal fluid, and PCNSV = primary CNS vasculitis.](BMRI2015-948497.005){#fig5}

###### 

Clinical and paraclinical findings in our three patients.

  Pt                                     1                                                                                2                                                                       3                                                                                                                                                                                                
  -------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------------------------------------- ------------------------------------------------------ ------------- --------------------------------------------------------------------
  Age/gender                             17/M                                                                             55/M                                                                    65/M                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                   
  Clinical presentation at onset         Headache, nausea and vomiting, diplopia, and weight loss                         Left leg monoparesis, headache, nausea and vomiting                     Recurrent confusional episodes                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                   
  MRI                                                                                                                                                                                                                                                                                                                                                                                              
   Time from symptom onset (weeks)       4                                                                                30                                                                      47                                                                                8.2                                       12.9                                                   1             21.4
   Hydrocephalus                         No                                                                               Modest dilation of ventricular system                                   *Tetra*-ventricular                                                               Triventricular                            Triventricular                                         No            Triventricular
   Leptomeningeal contrast enhancement   No                                                                               Contrast not administered                                               Supra- and infratentorial, cranial nerves, spinal cord, conus, and cauda equina   Supratentorial, conus, and cauda equina   Supratentorial, spinal cord, conus, and cauda equina   No            Supra- and infratentorial, cranial nerves, conus, and cauda equina
   Dural melanin deposits                No                                                                               No                                                                      Yes                                                                               No                                        No                                                     No            Yes
                                                                                                                                                                                                                                                                                                                                                                                                   
  CSF                                                                                                                                                                                                                                                                                                                                                                                               
   Time from symptom onset (weeks)       40.6                                                                             42.9                                                                    44.9                                                                              8.1                                       10.6                                                   14.9          21.4
   Glucose (mg/dL)                       ---                                                                              92                                                                      83                                                                                ---                                       ---                                                    29            8
   Proteins (mg/dL)                      ---                                                                              2366                                                                    2773                                                                              370                                       ---                                                    431           535
   Cell count (cells/uL)                 4                                                                                110                                                                     174                                                                               2                                         \<2                                                    10            36
   Cytology                              n.p.                                                                             Nonspecific                                                             Melanoma cells                                                                    n.p.                                      No identifiable cells                                  Nonspecific   Melanoma cells
                                                                                                                                                                                                                                                                                                                                                                                                   
  EEG                                    Poorly organized background activity with bilateral slow abnormalities           Diffuse bilateral slowing                                               Bilateral fronto-centrotemporal slow abnormalities with left prevalence                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                   
  Extra CNS visceral met                 No                                                                               No                                                                      No                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                   
  Final diagnosis                        **Primary leptomeningeal melanomatosis**                                         **Primary leptomeningeal melanomatosis**                                **Leptomeningeal carcinomatosis and cutaneous melanoma**                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                   
  Time to diagnosis (weeks)              47                                                                               17                                                                      23.4                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                   
  Clinical evolution                     Confusion, visual hallucinations, partial seizures, and behavioral alterations   Urinary retention, progressive paraparesis, and visual hallucinations   Vigilance impairment, generalized seizures, headache, and backache                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                   
  Treatment                              Temozolomide (I cycle)                                                           Dacarbazine (I cycle)                                                   None                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                   
  Overall survival (weeks)               49.1                                                                             23.4                                                                    30                                                                                                                                                                                               

Legend to [Table 1](#tab1){ref-type="table"}: CNS = central nervous system, CSF = cerebrospinal fluid, EEG = electroencephalogram, met = metastases, MRI = magnetic resonance imaging, n.p. = not performed, and --- = not available.
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